|
[1]FERLAY J, SHIN HR, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127 (12) :2893-2917.
|
|
[2]SIEGEL R, NAISHADHAM D, JEMAL A.Cancer Statistics, 2013[J].CA Cancer J Clin, 2013, 63 (1) :11-30.
|
|
[3] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.
|
|
[4]WITKOWSKI ER, SMITH JK, TSENG JF.Outcomes following resection of pancreatic cancer[J].J Surg Oncol, 2013, 107 (1) :97-103.
|
|
[5]BOSMAN FT, CARNEIRO F, HRUBAN RH, et al.WHO classification of tumours of the digestive system[M].Lyon:IARC, 2010.
|
|
[6]KONSTANTINIDIS IT, WARSHAW AL, ALLEN JN, et al.Pancreatic ductal adenocarcinoma:is there a survival difference for R1resections versus locally advanced unresectable tumors?What is a“true”R0resection?[J].Ann Surg, 2013, 257 (4) :731-736.
|
|
[7]IQBAL N, LOVEGROVE RE, TILNEY HS, et al.A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy:a meta-analysis of 1909 patients[J].Eur J Surg Oncol, 2009, 35 (1) :79-86.
|
|
[8]BAKER MS, BENTREM DJ, UJIKI MB, et al.A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy[J].Surgery, 2009, 146 (4) :635-643.
|
|
[9]NIGRI GR, ROSMAN AS, PETRUCCIANI N, et al.Metaanalysis of trials comparing minimally invasive and open distal pancreatectomies[J].Surg Endosc, 2011, 25 (5) :1642-1651.
|
|
[10]GILLEN S, SCHUSTER T, MEYER ZUM BSCHENFELDE C, et al.Preoperative/neoadjuvant therapy in pancreatic cancer:a systematic review and meta-analysis of response and resection percentages[J].PLoS Med, 2010, 7 (4) :e1000267.
|
|
[11]MOLLBERG N, RAHBARI NN, KOCH M, et al.Arterial resection during pancreatectomy for pancreatic cancer a systematic review and meta-analysis[J].Ann Surg, 2011, 254 (6) :882-893.
|
|
[12]JEURNINK SM, van EIJCK CH, STEYERBERG EW, et al.Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction:a systematic review[J].BMC Gastroenterol, 2007, 7:18.
|
|
[13]GURUSAMY KS, KUMAR S, DAVIDSON BR.Prophylactic gastrojejunostomy for unresectable periampullary carcinoma[J].Cochrane Database Syst Rev, 2013, 2:CD008533.
|
|
[14]NEOPTOLEMOS JP, STOCKEN DD, FRIESS H, et al.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J].N Engl J Med, 2004, 350 (12) :1200-1210.
|
|
[15]FUKUTOMI A, UESAKA K, BOKU N, et al.Randomized phaseⅢtrial of adjuvant chemotherapy with gemcitabine versus S'-1 for resected pancreatic cancer patients[J].J Clin Oncol, 2013, 13 (Suppl) :a4008.
|
|
[16]NEUHAUS P, RIESS H, POST S, et al.Final results of the randomized, prospective, multicenter phaseⅢtrial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC) [J].J Clin Oncol, 2008, 26 (15 Suppl) :a4504.
|
|
[17]NEOPTOLEMOS JP, MOORE MJ, COX TF, et al.Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma:the ESPAC-3 periampullary cancer randomized trial[J].JAMA, 2012, 308 (2) :147-156.
|
|
[18]von HOFF DD, ERVIN TJ, ARENA FP, et al.Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MAPACT) [C].ASCO Meeting Abstracts, 2013:LBA148.
|
|
[19]CONROY T, DESSEIGNE F, YCHOU M, et al.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J].N Engl J Med, 2011, 364 (19) :1817-1825.
|
|
[20]BURRIS HA 3rd, MOORE MJ, ANDERSEN J, et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol, 1997, 15 (6) :2403-2413.
|
|
[21]UENO H, IOKA T, IKEDA M, et al.Randomized phaseⅢstudy of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan:GEST study[J].J Clin Oncol, 2013, 31 (13) :1640-1648.
|
|
[22]NAKAI Y, ISAYAMA H, SASAKI T, et al.A multicentre randomised phaseⅡtrial of gemcitabine alone vs gemcitabine and S-1combination therapy in advanced pancreatic cancer:GEMSAP study[J].Br J Cancer, 2012, 106 (12) :1934-1939.
|
|
[23]CUNNINGHAM D, CHAU I, STOCKEN DD, et al.PhaseⅢrandomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J].J Clin Oncol, 2009, 27 (33) :5513-5518.
|
|
[24]HASSAN MM, BONDY ML, WOLFF RA, et al.Risk factors for pancreatic cancer:case-controlstudy[J].Am J Gastroenterol, 2007, 102 (12) :2696-2707.
|
|
[25]LYNCH SM, VRIELING A, LUBIN JH, et al.Cigarette smoking and pancreatic cancer:a pooled analysis from the pancreatic cancer cohort consortium[J].Am J Epidemiol, 2009, 170 (4) :403-413.
|
|
[26]BERK V, OZDEMIR N, OZKAN M, et al.XELOX vs.FOLFOX4 as second line chemotherapy in advanced pancreatic cancer[J].Hepatogastroenterology, 2012, 59 (120) :2635-2639.
|
|
[27]MOORE MJ, GOLDSTEIN D, HAMM J, et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol, 2007, 25 (15) :1960-1966.
|
|
[28]STRUMBERG D, SCHULTHEIS B, EBERT MP, et al.PhaseⅡ, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC) [C].ASCO Annual Meeting, 2013:a4009.
|
|
[29]SUDO K, YAMAGUCHI T, NAKAMURA K, et al.PhaseⅡstudy of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.PhaseⅡstudy of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer[J].Cancer Chemother Pharmacol, 2011, 67 (2) :249-254.
|
|
[30]MORIZANE C, OKUSAKA T, FURUSE J, et al.A phaseⅡstudy of S-1 in gemcitabine-refractory metastatic pancreatic cancer[J].Cancer Chemother Pharmacol, 2009, 63 (2) :313-319.
|
|
[31]TAKAHARA N, ISAYAMA H, NAKAI Y, et al.A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer[J].Cancer Chemother Pharmacol, 2013, 72 (5) :985-990.
|
|
[32]WANG J, XIA TY, WANG YJ, et al.Long-term results of gamma ray-based stereotacitc body radiation therapy in treatment of medically unfit or inoperable non-metastatic pancreatic adenocarcinoma[J].Int J Radiat Oncol Biol Phys, 2012, 84 (Suppl 3) :815-816.
|
|
[33]LI G, YU YY, HAN C, et al.Efficacy analysis of three-dimensional conformal radiotherapy with increasing dose in late course in81 cases of pancreatic cancer patients[J].J China Med Univ, 2012, 41 (12) :1134-1143. (in Chinese) 李光, 于洋洋, 韩冲, 等.81例胰腺癌后程加量三维适形放疗的疗效分析[J].中国医科大学学报, 2012, 41 (12) :1134-1143.
|
|
[34]CHANG D, XIA T, LI P, et al.Promising clinical outcome of stereotactic body radiation therapy for limited pancreatic carcinoma[J].Int J Radiat Oncol Biol Phys, 2010, 78 (3) :307.
|
|
[35]CHANG DS, XIA TY, LI P, et al.Clinical outcome of whole bodyγ-knife for limited pancreatic carcinoma[J].Chin J Radiat Oncol, 2009, 18 (6) :470-473. (in Chinese) 常冬姝, 夏廷毅, 李平, 等.全身γ刀治疗局限期胰腺癌临床结果分析[J].中华放射肿瘤学杂志, 2009, 18 (6) :470-473.
|
|
[36]XIA T, LI HQ, WANG J, et al.Clinical Outcome of Hypofractionated Radiation Therapy for Lung, Liver, and Pancreatic Cancer[J].Int J Radiat Oncol Biol Phys, 2010, 78 (Suppl 3) :574-575.
|
|
[37]STOCKEN DD, BUCHLER MW, DERVENIS C, et al.Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer[J].Br J Cancer, 2005, 92 (8) :1372-1381.
|
|
[38]KLEEFF J, MICHALSKI CW, FRIESS H, et al.Surgical treatment of pancreatic cancer:the role of adjuvant and multimodal therapies[J].Eur J Surg Oncol, 2007, 33 (7) :817-823.
|
|
[39]GAROFALO MC, REGINE WF, TAN MT, et al.On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer[J].Ann Surg, 2006, 244 (2) :332-333.
|
|
[40]Gastrointestinal Tumor Study Group.Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer[J].Cancer, 1987, 59 (12) :2006-2010.
|
|
[41]REGINE WF, WINTER KA, ABRAMS RA, et al.Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma:a randomized controlled trial[J].JAMA, 2008, 299 (9) :1019-1026.
|
|
[42]VAN LAETHEM JL, HAMMEL P, MORNEX F, et al.Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer:a randomized EORTC-40013-22012/FFCD-9203/GERCOR phaseⅡstudy[J].J Clin Oncol, 2010, 28 (29) :4450-4456.
|
|
[43]HERMAN JM, SWARTZ MJ, HSU CC, et al.Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas:results of a large, prospectively collected database at the Johns Hopkins Hospital[J].J Clin Oncol, 2008, 26 (21) :3503-3510.
|
|
[44]KALSER MH, ELLENBERG SS.Pancreatic cancer.Adjuvant combined radiation and chemotherapy following curative resection[J].Arch Surg, 1985, 120 (8) :899-903.
|
|
[45]MAXIMOUS DW, ABDEL-WANIS ME, EL-SAYED MI, et al.Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma[J].Int Arch Med, 2009, 2 (1) :7.
|
|
[46]WHITE RR, HURWITZ HI, MORSE MA, et al.Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas[J].Ann Surg Oncol, 2001, 8 (10) :758-765.
|
|
[47]LE SCODAN R, MORNEX F, GIRARD N, et al.Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma:feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review[J].Ann Oncol, 2009, 20 (8) :1387-1396.
|
|
[48]EVANS DB, VARADHACHARY GR, CRANE CH, et al.Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head[J].J Clin Oncol, 2008, 26 (21) :3496-3502.
|
|
[49]VARADHACHARY GR, WOLFF RA, CRANE CH, et al.Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head[J].J Clin Oncol, 2008, 26 (21) :3487-3495.
|
|
[50]IKEDA M, IOKA T, ITO Y, et al.A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2013, 85 (1) :163-169.
|
|
[51]BLACKSTOCK AW, TEPPER JE, NIEDWIECKI D, et al.Cancer and leukemia group B (CALGB) 89805:phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas[J].Int J Gastrointest Cancer, 2003, 34 (2-3) :107-116.
|
|
[52]HUGUET F, GIRARD N, GUERCHE CS, et al.Chemoradiotherapy in the management of locally advanced pancreatic carcinoma:a qualitative systematic review[J].J Clin Oncol, 2009, 27 (13) :2269-2277.
|
|
[53]KRISHNAN S, RANA V, JANJAN NA, et al.Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy[J].Cancer, 2007, 110 (1) :47-55.
|
|
[54]HUDSON E, HURT C, MORT D, et al.Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer:an effective and well-tolerated treatment[J].Clin Oncol (R Coll Radiol) , 2010, 22 (1) :27-35.
|
|
[55]RENI M, CEREDA S, BALZANO G, et al.Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma[J].Cancer Chemother Pharmacol, 2009, 64 (6) :1253-1259.
|
|
[56]KO AH, QUIVEY JM, VENOOK AP, et al.A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2007, 68 (3) :809-816.
|
|
[57]ZIMMERMANN FB, JEREMIC B, LERSCH C, et al.Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas[J].Hepatogastroenterology, 2005, 52 (61) :246-250.
|
|
[58]SPALDING AC, JEE KW, VINEBERG K, et al.Potential for doseescalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions[J].Med Phys, 2007, 34 (2) :521-529.
|
|
[59]YOVINO S, POPPE M, JABBOUR S, et al.Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers[J].Int J Radiat Oncol Biol Phys, 2011, 79 (1) :158-162.
|
|
[60]HUGUET F, GOODMAN KA, AZRIA D, et al.Radiotherapy technical considerations in the management of locally advanced pancreatic cancer:American-French consensus recommendations[J].Int J Radiat Oncol Biol Phys, 2012, 83 (5) :1355-1364.
|
|
[61]LOEHRER PJ SR, FENG Y, CARDENES H, et al.Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer:an Eastern Cooperative Oncology Group trial[J].J Clin Oncol, 2011, 29 (31) :4105-4112.
|
|
[62]MURPHY JD, ADUSUMILLI S, GRIFFITH KA, et al:Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2007, 68 (3) :801-808.
|
|
[63]WILKOWSKI R, THOMA M, WEINGANDT H, et al.Chemoradiation for ductal pancreatic carcinoma:principles of combining chemotherapy with radiation, definition of target volume and radiation dose[J].Jop, 2005, 6 (3) :216-230.
|
|
[64]JINGU K, TANABE T, NEMOTO K, et al.Intraoperative radiotherapy for pancreatic cancer:30-year experience in a single institution in Japan[J].Int J Radiat oOncol Biol Phys, 2012, 83 (4) :e507-e511.
|
|
[65]CRANE CH, BEDDAR AS, EVANS DB.The role of intraoperative radiotherapy in pancreatic cancer[J].Surg Oncol Clin N Am, 2003, 12 (4) :965-977.
|
|
[66]HAMMEL P.Chemoradiotherapy offers no advantage in locally advanced pancreatic cancer[EB/OL]. (2013-07-04) [2014-02-20].http://am.asco.org/chemoradiotherapy-offers-advantage-locally-advanced-pancreatic-cancer.
|
|
[67]FEARON K, STRASSER F, ANKER SD, et al.Definition and classification of cancer cachexia:an international consensus[J].Lancet Oncol, 2011, 12 (5) :489-495.
|
|
[68]LUNDHOLM K, DANERYD P, BOSAEUS I, et al.Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease:effects on survival, metabolism, and function[J].Cancer, 2004, 100 (9) :1967-1977.
|
|
[69]RUIZ-GARCIA V, JUAN O, PEREZ HOYOS S, et al.Megestrol acetate:systematic review usefulness about the weight gain in neoplastic patients with cachexia[J].Med Clin (Barc) , 2002, 119 (5) :166-170.
|
|
[70]BABCOCK T, HELTON WS, ESPAT NJ.Eicosapentaenoic acid (EPA) :an anti-inflammatory omega-3 fat with potential clinical applications[J].Nutrition, 2000, 16 (11-12) :1116-1118.
|
|
[71]GAO JQ, WU GH, YUAN L, et al.The effect of using omega-3polyunsaturated fatty acid in tumor-bearing rats[J].J Surg Concepts&Pract, 2008, 13 (5) :419-422. (in Chinese) 高佳琦, 吴国豪, 袁磊, 等.ω-3多不饱和脂肪酸对改善荷瘤大鼠营养状况的作用[J].外科理论与实践, 2008, 13 (5) :419-422.
|
|
[72]FETTERI NR, METUFFIC JC, CARROLL MA, et al.Renal cox-2 cytokines and 20-hete:tubular and vascular mechanisms[J].Curr Parm Design, 2004, 10 (6) :613-626.
|
|
[73]GORDON JN, TREBBLE TM, ELLIS RD, et al.Thalidomide in the treatment of cancer cachexia:a randomised placebo controlled trial[J].Gut, 2005, 54 (4) :540-545.
|
|
[74]YU JH, LIU P.KLT treatment of pancreatic cancer research progress[J].Anhui Med Pharm J, 2007, 11 (4) :354-355. (in Chinese) 于江华, 刘平.康莱特注射液治疗胰腺癌研究进展[J].安徽医药, 2007, 11 (4) :354-355.
|
|
[75]LI YS.New progress in advanced pancreatic cancer treatment KLT[J].Chin J Clin Oncol, 2012, 39 (16) :1158-1160. (in Chinese) 李玉升.康莱特注射液治疗晚期胰腺癌新进展[J].中国肿瘤临床, 2012, 39 (16) :1158-1160.
|
DownLoad: